Immunomodulatory enzyme technology company Hansa Biopharma AB (NASDAQ Stockholm: HNSA) revealed on Friday the completion of the sale its entire equity stake in Genovis AB (NASDAQ Stockholm:GENO) for gross proceeds of SEK89m.
Proceeds may be used by Hansa for working capital, to expedite the clinical development programme of imlifidase in transplant rejection and autoimmune diseases, to ramp up preparations for clinical studies with the recently selected lead in the NiceR-programme for development of novel IgG-cleaving enzymes for repeat dosing.
Genovis is reportedly engaged in the development of enzymatic research tools and technologies, applied in e.g. development and quality control of antibody-based drugs.
Earlier in 2011, Hansa Biopharma made a strategic and financial investment in Genovis.
(EUR1=SEK10.4685)
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study